- 関
- u-PA、urinary plasminogen activator、urokinase
- 同
- uPA
WordNet
- write by means of a keyboard with types; "type the acceptance letter, please" (同)typewrite
- a small metal block bearing a raised character on one end; produces a printed character when inked and pressed on paper; "he dropped a case of type, so they made him pick them up"
- (biology) the taxonomic group whose characteristics are used to define the next higher taxon
- a subdivision of a particular kind of thing; "what type of sculpture do you prefer?"
- all of the tokens of the same symbol; "the word `element contains five different types of character"
- printed characters; "small type is hard to read"
- identify as belonging to a certain type; "Such people can practically be typed" (同)typecast
- (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
- an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents
- writing done with a typewriter (同)typewriting
PrepTutorEJDIC
- 〈C〉(…の)『型』,タイプ,類型,種類(kind)《+of+名》 / 〈C〉(その種類の特質を最もよく表している)『典型』,手本,模範《+of+名》 / 〈U〉《集合的に》活字;〈C〉(1個の)活字 / 〈U〉(印刷された)字体,活字 / 〈C〉(貨幣・メダルなどの)模様,図柄 / 〈C〉血液型(blood group) / …‘を'タイプに打つ / (…として)…‘を'分類する《+名+as+名(doing)》 / …‘の'型を決める / タイプライターを打つ
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
- Eastman BM, Jo M, Webb DL, Takimoto S, Gonias SL.AbstractBinding of urokinase-type plasminogen activator (uPA) to its receptor, uPAR, in estrogen receptor-α (ERα) expressing breast cancer cells, transiently activates ERK downstream of FAK, Src family kinases, and H-Ras. Herein, we show that when uPAR is over-expressed, in two separate ERα-positive breast cancer cell lines, ERK activation occurs autonomously of uPA and is sustained. Autonomous ERK activation by uPAR requires H-Ras and Rac1. A mutated form of uPAR, which does not bind vitronectin (uPAR-W32A), failed to induce autonomous ERK activation. Expression of human uPAR or mouse uPAR but not uPAR-W32A in MCF-7 cells provided a selection advantage when these cells were deprived of estrogen in cell culture for two weeks. Similarly, MCF-7 cells that express mouse uPAR formed xenografts in SCID mice that survived and increased in volume in the absence of estrogen supplementation, probably reflecting the pro-survival activity of phospho-ERK. Autonomous uPAR signaling to ERK was sensitive to the EGFR tyrosine kinase inhibitors, Erlotinib and Gefitinib. The transition in uPAR signaling from uPA-dependent and transient to autonomous and sustained is reminiscent of the transformation in ErbB2/HER2 signaling observed when this gene is amplified in breast cancer. uPAR over-expression may provide a pathway for escape of breast cancer cells from ERα-targeting therapeutics.
- Cellular signalling.Cell Signal.2012 Sep;24(9):1847-55. Epub 2012 May 19.
- Binding of urokinase-type plasminogen activator (uPA) to its receptor, uPAR, in estrogen receptor-α (ERα) expressing breast cancer cells, transiently activates ERK downstream of FAK, Src family kinases, and H-Ras. Herein, we show that when uPAR is over-expressed, in two separate ERα-positive brea
- PMID 22617030
- Measuring net protease activities in biological samples using selective peptidic inhibitors.
- Pollaro L, Diderich P, Angelini A, Bellotto S, Wegner H, Heinis C.SourceInstitute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
- Analytical biochemistry.Anal Biochem.2012 Aug 1;427(1):18-20. Epub 2012 Apr 28.
- The measurement of activities from individual proteases in biological samples is difficult because of the numerous proteases, their overlapping activities, and the lack of specific substrates. We applied selective protease inhibitors based on bicyclic peptides (>2000-fold selective over related p
- PMID 22549049
Japanese Journal
- A novel animal model for in vivo study of liver cancer metastasis
- Fujiwara Shinsuke,Fujioka Hikaru,Tateno Chise,Taniguchi Ken,Ito Masahiro,Ohishi Hiroshi,Utoh Rie,Ishibashi Hiromi,Kanematsu Takashi,Yoshizato Katsutoshi
- World Journal of Gastroenterology 18(29), 3875-3882, 2012-08-07
- … METHODS: Cell transplantation into mouse livers was conducted using alpha-fetoprotein (AFP)-producing human gastric cancer cells (h-GCCs) and h-hepatocytes as donor cells in a transgenic mouse line expressing urokinase-type plasminogen activator (uPA) driven by the albumin enhancer/promoter crossed with a severe combined immunodeficient (SCID) mouse line (uPA/ SCID mice). …
- NAID 120005082419
- 審査論文 ヒト線維芽細胞培養系を用いたセイヨウオトギリソウ抽出物の創傷治癒に及ぼす効果
Related Links
- DrugBank ID Drug Name Drug Type Drug Groups 1 DB07129 (2R)-1-(2,6-dimethylphenoxy)propan-2-amine small molecule experimental 2 DB04172 [2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta ...
- Urokinase-Type Plasminogen Activator Urokinase-type plasminogen activator is a strong plasminogen activator which specifically cleaves the proenzyme/zymogen plasminogen to form the active enzyme plasmin. It specifically ...
★リンクテーブル★
[★]
- 関
- urinary plasminogen activator、urokinase、urokinase-type plasminogen activator
[★]
- 英
- urokinase-type plasminogen activator、u-PA
- 関
- ウロキナーゼ、尿プラスミノーゲン活性化酵素
-u-PA
[★]
尿プラスミノーゲン活性化酵素
- 関
- u-PA、urokinase、urokinase-type plasminogen activator
[★]
- (windows)ファイル内容表示(linux -> cat])
- ex. type report_20111118.jp.htm | php a.php > report_20111118.jp.jp.jp.html
- 関
- form、mode、pattern、type specimen、typed
[★]
[★]
- 関
- form、mode、pattern、type
[★]
[★]
プラスミノーゲンアクチベーター, PA